NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Safety and Tolerability of Multiple Inhaled NVA237 Doses in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2008-01-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00545311
- Locations
- 🇩🇪
Novartis Investigative Site, Munich, Germany
🇩🇪Novartis investigative site, Moenchengladbach, Germany
🇩🇰Novartis Investigative site, Copenhagen, Denmark
Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 13
- Registration Number
- NCT00545259
- Locations
- 🇨🇭
Novartis investigative site, Zurich, Switzerland
🇮🇹Novartis Investigative Site, Padova, Italy
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
Phase 4
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 178
- Registration Number
- NCT00542269
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 171
- Registration Number
- NCT00537082
- Locations
- 🇯🇵
Novartis, Iwate, Japan
🇯🇵Novartis Investigative Site, Wakayama, Japan
🇯🇵Novartis Investigative site, Sapporo-shi, Hokkaido, Japan
Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00532350
- Locations
- 🇩🇪
Novartis investigative site, Berlin, Germany
🇩🇪Novartis Investigative site, Wiesbaden, Germany
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 27
- Registration Number
- NCT00531050
- Locations
- 🇧🇪
Novartis Investigative site, Antwerp, Belgium
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1613
- Registration Number
- NCT00529451
- Locations
- 🇹🇭
Novartis Investigative Sites, Thailand, Thailand
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 257
- Registration Number
- NCT00523744
- Locations
30 sites in Germany
🇩🇪Novartis Investigative Site, , Germany, Schwerin, Germany
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00518765
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00515424
© Copyright 2024. All Rights Reserved by MedPath